Knicks roll into Salt Lake City, out to extend Jazz's woes

VANCOUVER - A pet food company in Oregon sent out a voluntary recall after a house cat died from eating its products, which tested positive for bird flu, and the company says the same contaminated batch was sold in British Columbia. Read this article for free: Already have an account? To continue reading, please subscribe: * VANCOUVER - A pet food company in Oregon sent out a voluntary recall after a house cat died from eating its products, which tested positive for bird flu, and the company says the same contaminated batch was sold in British Columbia. Read unlimited articles for free today: Already have an account? VANCOUVER – A pet food company in Oregon sent out a voluntary recall after a house cat died from eating its products, which tested positive for bird flu, and the company says the same contaminated batch was sold in British Columbia. Northwest Naturals in Portland, Oregon, says in a statement that it is recalling one batch of its two-pound Feline Turkey Recipe raw frozen pet food after it tested positive for highly pathogenic avian influenza virus. The company says the same product was sold in several states including California, Colorado, Washington and B.C. in Canada. The Oregon Department of Agriculture says in a warning issued on Thursday that tests confirm that a house cat in Washington County was infected with H5N1 and died after consuming the raw frozen pet food sold by Northwest Naturals. The test results have triggered a nationwide voluntary recall with the company alerting consumers to check their products. The recall applies to products packaged in two-pound plastic bags with “Best if used by” dates between May 21, 2026, and June 23, 2026. Northwest Naturals says customers who have purchased the recalled product should immediately throw away the product. Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. Dr. Ryan Scholz, a state veterinarian with the Oregon Department of Agriculture, says in a statement that they are confident that this cat contracted bird flu by eating Northwest Naturals raw and frozen pet food, especially since this cat was “strictly an indoor cat,” which could not be exposed to the virus in its living environment. The Oregon Department of Agriculture says to date, no human cases of bird flu have been linked to the incident. It also says this case reminds pet owners that feeding raw meat to pets can lead to severe illness and these harmful pathogens, including H5N1, can be destroyed when meat is thoroughly cooked. Health Canada hasn’t officially recalled the products and it has not yet responded to media requests. This report by The Canadian Press was first published Dec. 26, 2024. Advertisement AdvertisementUS auto giant General Motors announced Tuesday it will abandon its robotaxi development efforts after a highly publicized incident last year stymied its progress in the autonomous vehicle field. The Detroit-based manufacturer plans to merge the Cruise robotaxi vehicle unit with GM's technical teams to concentrate on developing advanced driver assistance systems for personal vehicles, a statement said. The company said it abandoned the Cruise project "given the considerable time and resources that would be needed to scale the business, along with an increasingly competitive robotaxi market." It marks a major turnaround for GM, which bought the Cruise startup in 2016 and has since spent billions of dollars to make the operation viable. "A robotaxi business is not General Motors’ core business," said GM CEO Mary Barra in a call with analysts. But Barra said GM's commitment to autonomous technology "is unwavering." The halt of operations comes a year after Cruise was forced to suspend all operations in San Francisco after one of its self-driving cars dragged a woman who had first been hit by a hit-and-run driver in the city. Cruise lost its operating permits from regulators, paused expansions into other states and laid off 900 employees -- a quarter of its workforce. Shortly before the incident, California authorities had allowed for expanded driverless taxi services in San Francisco, giving the go-ahead for Alphabet-owned Waymo and Cruise. More from this section Cruise's exit confirms Waymo as the dominant player in the business, which was valued at $45 billion after a fundraising round in October, according to Bloomberg. The company has been expanding its reach and currently runs robotaxi fleets in San Francisco, Phoenix and Los Angeles. And in a team-up with Uber, the company is planning to offer Waymo robotaxi rides in Atlanta and Austin. Amazon's Zoox meanwhile is conducting robotaxi testing in California and Las Vegas, while Elon Musk recently unveiled what he said was a robotaxi capable of self-driving, predicting it would be available by 2027. GM's strategic pivot comes as embattled automakers worldwide face mounting pressure to balance investments in emerging technologies with near-term profitability. The auto giant said that the restructuring is expected to generate annual savings exceeding $1 billion once completed in the first half of 2025. GM's share price was up by more than three percent in after hours trading on Wall Street. arp/dw

How important is it to have a strong substitute bench in football?SANTA CLARA, Calif. (AP) — Dan Campbell stood at the podium after Detroit blew a 17-point lead to San Francisco in last season's NFC title game and talked about how that might have been the Lions' only shot at reaching the Super Bowl. The coach knew how difficult it would be to maintain that high level of play through injuries, attrition and with a target on their back as a top contender in the NFC. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Total Monthly Digital Colocation Revenue grew 111% Y/Y in November 2024 Total Current Operating Hash Rate (EH) of about 4.98 EH/s, with current total operating capacity of 129 MW and expected to grow to 153 MW upon Ohio facility completion MIDLAND, Pa., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Mawson Infrastructure Group Inc. MIGI ("Mawson" or "the Company"), a publicly-traded technology company focused on digital infrastructure platforms for artificial intelligence (AI), high-performance computing (HPC), and digital assets markets, today announced its unaudited business and operational update for November 2024. Rahul Mewawalla, CEO and President said, "We are pleased to deliver another month of growth across our businesses with our total monthly revenue increasing year-over-year and month-over-month, highlighted by significant growth in our digital colocation revenue of 111% year-over-year. Following our recent honor of ringing the NASDAQ Closing Bell in celebration of the Company's transformation, we continue to advance our innovative approach to providing digital infrastructure platforms and solutions. Our synergistic business portfolio and our enhanced strategic, operational, and technological capabilities are expected to continue to be a competitive advantage for us moving forward." Unaudited financial and operational highlights for November 2024: Monthly Digital Colocation Revenue was up 111% Y/Y, growing from $1.98 million in November 2023 to about $4.18 million in November 2024. Total Monthly Revenue of about $4.91 million, up 2% Y/Y from November 2023 and up 0.5% M/M from October 2024; Monthly Energy Management Revenue of $0.33 million and Monthly Digital Assets Mining Revenue of $0.40 million. Current Total Operating Capacity of 129 MW and expected to grow to 153 MW upon full completion of Ohio facility. Combined Total Current Operating Hash Rate (EH) of about 4.98 EH/s (includes colocation and self-mining) 1 . Mawson supports innovative, agile, efficient, and scalable approaches to AI infrastructure and compute, and invites AI/HPC ecosystem companies to discuss opportunities to collaborate on artificial intelligence, high-performance and accelerated computing solutions. Conferences and Events Update Mawson has planned for its CEO and President, Rahul Mewawalla to participate in the following upcoming conferences and events. Please contact IR@Mawsoninc.com for further information. Northland Capital Markets Growth Conference - December 12, 2024 Axios Artificial Intelligence (AI) Summit – December 16-17, 2024 in San Francisco ICR Conference 2025 – January 13-15, 2025 in Orlando Pacific Telecommunications Council - January 20-22, 2025 in Honolulu About Mawson Infrastructure Mawson Infrastructure Group MIGI is a technology company that offers digital infrastructure platforms for AI, HPC, and digital assets. The Company's digital infrastructure platforms can be used to operate computing resources for a number of applications, and are offered across digital assets, artificial intelligence (AI), high-performance computing (HPC) and other computing applications. Our innovation, technology, and operational expertise enables us to operate and optimize digital infrastructure to accelerate the digital economy. The Company has a strategy to prioritize the usage of carbon-free energy sources, including nuclear energy, to power its digital infrastructure platforms and computational machines. For more information, please visit: https://www.mawsoninc.com . CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS The Company cautions that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as "expect," "intend," "plan," "anticipate," "believe," and "will," among others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" included in the Company's Annual Report on Form 10-K filed with the SEC on April 1, 2024, Quarterly Reports on Form 10-Q filed with the SEC on May 15, 2024, August 19, 2024, November 14, 2024, the Report on Form 8-K filed with the SEC on December 4, 2024, and in other filings that the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. For more information, visit us at https://www.mawsoninc.com LinkedIn: https://www.linkedin.com/company/mawsoninc/ Twitter: Mawson (@Mawsoninc) / X (twitter.com) Facebook: Mawson Inc | Pittsburgh PA | Facebook YouTube: https://www.youtube.com/c/MawsonInc Vimeo: https://vimeo.com/mawsoninc Investor Contact: Investor Relations Team IR@mawsoninc.com Partnerships Contact: Partnerships Team Partnerships@mawsoninc.com Media and Press Contact: Media Relations Team mediarelations@mawsoninc.com Share this press release Twitter LinkedIn ___________________________ 1 Current Operating Hash Rate is based on the nameplate hash rate of the miners currently deployed. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.NASHVILLE, Tenn. (WTVF) — We're told the gun used in the murder of United HealthCare CEO Brian Thompson was a so-called ghost gun. Simply put, privately manufactured firearms are guns without serial numbers that can be pieced together with a 3D printer, the computer code and some skill. "Technology has advanced in leaps and bounds, which has allowed a lot of hobbyists and innovators to purchase 3D printers and source CAD files that allow them to print things like frames, and receivers and then construct them at home into a working firearm," said Corell Thomas. Corell Thomas has spent his whole career either in the military or in private security. He is the vice president of operations at Fortified Risk Group. DIY firearms are generally legal in Tennessee. As long as they are not manufactured to be sold, 3D printing a gun for personal use does not require special permissions. "Unless you are intent on selling said 3D printed firearm or giving it to someone, it is technically legal in the state of Tennessee for you to have an unserialized firearm," Thomas said. Certain types of firearms that are regulated under the National Firearms Act cannot be 3D printed without going through the proper protocols. Those include machine guns, short-barreled rifles, short-barreled shotguns, silencers and destructive devices with suppressors. When it was first enacted in the 1930s, the underlying purpose of the NFA was to discourage transactions of firearms frequently used in crimes. As you can imagine, these guns have both critics and supporters. Groups like Everytown for Gun Safety propose the spread of the computer code that is used to 3D print the firearm or its parts needs to be stopped. Those who want to put an end to 3D printed guns have a bit of an uphill battle as 3D printers have simplified the manufacturing process in other industries, like the automobile and prosthetic industry. "So it becomes the question of where do we draw the line where we're not prohibiting innovation in areas we need it in order to stop a percentage of nefarious actors," Thomas said. Between 2016 and 2021, the ATF received more than 45,000 reports of so-called ghost guns used in a crime. Do you have more information about this story? You can email me at hannah.mcdonald@newschannel5.com . Rebecca: https://ewscripps.brightspotcdn.com/a2/d9/fb69982545c59e9836fbe80fe431/rebecca-recommends.png Bree: https://ewscripps.brightspotcdn.com/74/78/507118fa415f9ad794a927fe43ca/screenshot-2024-12-09-at-5-09-02-am.png Carrie: https://ewscripps.brightspotcdn.com/2e/72/be0f23854c54a228c9d6138c9847/carrie-recommends-header.png Ben: https://ewscripps.brightspotcdn.com/df/c4/19fa7c504480938f39a431e3b276/ben-recommends-header.png Amy: https://ewscripps.brightspotcdn.com/b9/b6/1408516a4a91b97639b178fc1ba9/amy-recommends-header.png Rhori: https://ewscripps.brightspotcdn.com/5b/25/a224d13d47739165c92b94e643db/rhori-recommends-header.png Lelan: https://ewscripps.brightspotcdn.com/af/54/833bf879454097a398bd44f723de/lelan-recommends.png Fostering Hope provides Christmas for kids in foster care. I'm delighted to see Fostering Hope expand this year to expand their reach to now include kids in Foster care in metro AND foster kids in East TN hard hit by Helene. -Bree Smith

India's office property market scaled a fresh peak in 2024, clocking the third straight year of record leasing, aided by robust demand from multinationals for setting up global capability centres, and flexible workspace operators. ET Year-end Special Reads It's all Gucci for Indians' luxury craving even as economy shows wrinkles Investing in 2025: Will domestic funds continue to counter FPI sell-offs amid rising valuations? 2024 exposed the underbelly of India's Silicon Valley Leasing activity in the office market across the top six cities touched 66.4 million sq ft, up 14% from a year ago, showed data from real estate services firm Colliers India . Bengaluru drove Grade A office space demand, with the highest-ever leasing volume of 21.7 million sq ft, up 40%. Hyderabad and Mumbai recorded leasing volume of 12.5 million sq ft and 10.0 million sq ft leasing, respectively. Both cities reported double-digit annual office space demand for the first time this calendar year. Delhi-NCR too saw healthy space uptake with Grade A demand nearly reaching the 10 million sq ft mark. ET Bureau "Three out of the six major cities witnessed more than 10 million sq ft of annual leasing. Bengaluru especially witnessed remarkably strong demand of close to 22 million sq feet and accounted for one-third of the total space uptake in 2024. New supply during the year also remained above the 50 million sq ft mark and kept vacancy levels range bound," said Arpit Mehrotra, MD, Office Services, India, Colliers. Demand in 2025 can potentially stabilise at elevated levels and annual space uptake exceeding 60 million sq feet is likely to be the new norm over the next few years, he added. On the supply side, new completions touched to 53.3 million sq ft for the year, a 6% rise from 2023. Flex space demand hit a record 12.5 million sq feet, a 45% growth from last year. Web Development 12-Factor App Methodology: Principles and Guidelines By - Prince Patni, Software Developer (BI, Data Science) View Program Data Analysis Learn Power BI with Microsoft Fabric: Complete Course By - Prince Patni, Software Developer (BI, Data Science) View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Design Canva Magic Write: Ideas to Stunning Slides in No Time By - Prince Patni, Software Developer (BI, Data Science) View Program Web Development Advanced Java Mastery: Object-Oriented Programming Techniques By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Financial Literacy for Non-Finance Executives By - CA Raja, Chartered Accountant | Financial Management Educator | Former AVP - Credit, SBI View Program Web Development JavaScript Essentials: Unlock AI-Driven Insights with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Collaborative AI Foundations: Working Smarter with Machines By - Prince Patni, Software Developer (BI, Data Science) View Program Marketing Future of Marketing & Branding Masterclass By - Dr. David Aaker, Professor Emeritus at the Haas School of Business, UC Berkeley, Author | Speaker | Thought Leader | Branding Consultant View Program Finance Crypto & NFT Mastery: From Basics to Advanced By - CA Raj K Agrawal, Chartered Accountant View Program Entrepreneurship Startup Fundraising: Essential Tactics for Securing Capital By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Entrepreneurship Crafting a Powerful Startup Value Proposition By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Finance Financial Literacy i.e Lets Crack the Billionaire Code By - CA Rahul Gupta, CA with 10+ years of experience and Accounting Educator View Program Leadership Business Storytelling Masterclass By - Ameen Haque, Founder of Storywallahs View Program Marketing Digital Marketing Masterclass by Neil Patel By - Neil Patel, Co-Founder and Author at Neil Patel Digital Digital Marketing Guru View Program Artificial Intelligence(AI) AI and Analytics based Business Strategy By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI View Program Entrepreneurship Building Your Winning Startup Team: Key Strategies for Success By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Legal Complete Guide to AI Governance and Compliance By - Prince Patni, Software Developer (BI, Data Science) View Program Entrepreneurship Marketing & Sales Strategies for Startups: From Concept to Conversion By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Artificial Intelligence(AI) Master in Python Language Quickly Using the ChatGPT Open AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Flex spaces comprised nearly a fifth of Grade A space uptake in 2024. "Flex operators accounted for almost 20% of the India office space demand in 2024, up from 5-15% share in each of the years starting 2020. The occupier preference for managed office spaces augurs well for leading operators, who are likely to increasingly foray into Tier-II/III cities throughout 2025 and expedite their fundraising plans through primary markets as well," said Vimal Nadar, senior director and head of research, Colliers India. BFSI and engineering & manufacturing sectors too demonstrated healthy leasing activity, both crossing the 10 million sq feet leasing in 2024. Notably, large-sized deals of more than 100,000 sq feet continued to drive leasing activity and contributed to 54% of total demand in 2024. Large-sized deals were particularly preferred by occupiers from the technology sector and flex spaces as well. Nominations for ET MSME Awards are now open. The last day to apply is December 31, 2024. Click here to submit your entry for any one or more of the 22 categories and stand a chance to win a prestigious award. (You can now subscribe to our Economic Times WhatsApp channel )

New York, USA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Neuroendocrine Tumors Market to Showcase Rapid Growth During the Study Period (2020–2034), at a CAGR of 5.1%| DelveInsight The launch of upcoming therapies such as ITM-11, CAM2029, RYZ101, CABOMETYX, ALPHAMEDIX, and others in the forecast period, rising incident population due to an increased number of endoscopic and radio-imaging studies, increasing research activities are driving neuroendocrine tumor market size. Companies such as Novartis, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda, and others are competing fiercely to capture the largest market sizes. DelveInsight’s latest Neuroendocrine Tumors Market Insights report includes a comprehensive understanding of current treatment practices, emerging neuroendocrine tumor drugs, market share of individual therapies, and current and forecasted neuroendocrine tumors market size from 2020 to 2034, segmented into 6MM [the United States, the EU4 (Germany, France, Italy, and Spain), and the United Kingdom]. Key Takeaways from the Neuroendocrine Tumors Market Report According to DelveInsight’s analysis, the market size of neuroendocrine tumors in the US was USD 1.5 billion in 2023. In 2023, Somatostatin analogs (SSAs) captured the highest market size of approximately USD 700 million in the US, followed by LUTATHERA . However, by 2034, radioligand treatments including approved beta emitter-radioligand therapy [LUTATHERA], and most anticipated alpha emitter-based therapies are expected to drive the overall NETs market size. The total number of incident cases of NETs in the US was nearly 29,500 cases in 2023 and is projected to increase by 2034. Prominent emerging companies working in the domain of neuroendocrine tumors, including ITM Solucin GMBH , Camurus , Bristol Myers Squibb , Rayzebio , Exelixis , Ipsen , Takeda , Radiomedix , Orano Med , Perspective Therapeutics , Elicera Therapeutics , Chimerix , Enterome , Teclison , and others, are actively working on innovative neuroendocrine tumor drugs. These novel neuroendocrine tumor therapies are anticipated to enter the neuroendocrine tumors market in the forecast period and are expected to change the market. Some of the key emerging neuroendocrine tumor treatments include ITM-11 (N.C.A. 177LU-EDOTREOTIDE), CAM2029, RYZ101 (ACTINIUM-225 DOTATATE), CABOMETYX (Cabozantinib), ALPHAMEDIX (212PB-DOTAMTATE), [212PB] VMT- -NET , ELC-100 (ADVINCE), ONC201 , EO2401 + NIVOLUMAB , TIRAPAZAMINE (TEC-001) , and others. As the field of radioligand therapy evolves, there is an exciting shift towards alpha-emitting radioisotopes. At present, only beta-emitting radioisotopes are currently approved, companies are now focusing on developing alpha-emitters. In August 2024, Exelixis announced that its supplemental New Drug Application (sNDA) for CABOMETYX has been accepted in the US for: 1) the treatment of adults with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pancreatic neuroendocrine tumors (pNET), and 2) the treatment of adults with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated extra-pancreatic NET (epNET). The US Food and Drug Administration (FDA) assigned a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of April 3, 2025. In July 2024 , Curium announced that it had submitted its 505(b)(2) NDA for Lutetium Lu 177 Dotatate Injection for the treatment of somatostatin receptor-positive (SSTR+) GEP-NETS. In April 2024, Novartis announced that the US FDA approved LUTATHERA for the treatment of pediatric patients 12 years and older with SSTR+ GEP-NETs, including foregut, midgut, and hindgut NETs. Discover which therapies are expected to grab the NETs market share @ Neuroendocrine Tumors Market Report Neuroendocrine Tumors Overview Neuroendocrine Tumors (NETs) are a diverse group of cancers that arise from neuroendocrine cells, which have characteristics of both nerve cells and hormone-producing cells. These tumors can develop anywhere in the body but are most commonly found in the gastrointestinal tract, pancreas, and lungs. The exact causes of neuroendocrine tumors are not fully understood, but certain factors may increase risk, including genetic syndromes like multiple endocrine neoplasia type 1 (MEN1), Von Hippel-Lindau disease, and neurofibromatosis. Other potential contributors include chronic inflammatory conditions, smoking, and exposure to certain chemicals. Symptoms of NETs can vary widely depending on the tumor's location and whether it secretes hormones. Some tumors may be asymptomatic for a long time. Common symptoms include abdominal pain, diarrhea, flushing of the skin, unexplained weight loss, and in cases of hormone-secreting tumors, symptoms related to excess hormones, such as changes in blood sugar levels or high blood pressure. Diagnosing NETs typically involves a combination of blood and urine tests to detect hormone levels, imaging studies like CT, MRI, or PET scans, and biopsies to analyze tumor tissue. Specialized tests like chromogranin A (CgA) blood tests or somatostatin receptor scintigraphy (Octreoscan) may also be used to identify neuroendocrine activity and locate tumors. Neuroendocrine Tumors Epidemiology Segmentation The neuroendocrine tumors epidemiology section provides insights into the historical and current neuroendocrine tumors patient pool and forecasted trends for the 6MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The neuroendocrine tumors market report proffers epidemiological analysis for the study period 2020–2034 in the 6MM segmented into: Total Incident Cases of NET Cases of NETs by Grade Stage-specific Cases of NET Cases of NETs by Site Cases of NETs by Functional Status Download the report to understand which factors are driving NETs epidemiology trends @ Neuroendocrine Tumors Epidemiological Insights Neuroendocrine Tumors Treatment Market Surgery is generally considered a first-line treatment for localized NETs. The frontline treatment for metastatic disease is somatostatin analogs, and currently, two agents are FDA-approved: SANDOSTATIN (octreotide acetate) and SOMATULINE DEPOT (lanreotide). Both somatostatin analogs provide symptomatic relief in 50% to 70% of patients and biochemical responses in 40% to 60% of patients. Traditionally, mTOR inhibitor – everolimus or sunitinib – was acknowledged as a second-line agent, but with the recent approval of PRRT (peptide receptor radionuclide therapy), the choice of second-line therapy is debatable. While GEP-NETs in children and adolescents are rare, the impact can be devastating. Advanced Accelerator Applications (AAA)/Novartis’s LUTATHERA is now the very first therapy approved specifically for use in pediatric patients with GEP-NETs. offering new hope to young patients living with this rare cancer. In January 2018, the FDA approved LUTATHERA, a radiolabeled somatostatin analog for the treatment of GEP-NETs. In April 2024, Novartis announced that the US FDA approved LUTATHERA for the treatment of pediatric patients 12 years and older with SSTR+ GEP-NETs, including foregut, midgut, and hindgut NETs. LUTATHERA is also approved in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NETs in adults, and in Japan for SSTR-positive NETs. All available therapies for NETs, whether monotherapy or combination, are currently leveraged to treat this complex, diverse population of patients, yet no treatment has maintained progression-free survival (PFS) indefinitely. At present, the NETs market is dominated by SSAs, however, by 2034, radioligand therapies are projected to capture the highest market share, reflecting a paradigm shift driven by their enhanced efficacy and the growing adoption of targeted treatment approaches. While LUTATHERA has primarily been used as a second-line treatment, there is a growing interest in expanding its use to first-line settings for medium- and high-risk NETs. This trend underscores the rising prominence of radioligand therapies in redefining treatment standards in the NETs space. Learn more about the market of NETs @ Neuroendocrine Tumors Treatment Neuroendocrine Tumors Emerging Drugs and Companies Some of the drugs in the pipeline include ITM-11 (ITM Isotope Technologies Munich), CABOMETYX (Exelixis/Ipsen/Takeda), CAM2029 (Camurus), AlphaMedix (Radiomedix/Orano Med), VMT- -NET (Perspective Therapeutics), and others. CABOMETYX (cabozantinib) is a small-molecule inhibitor targeting several receptor tyrosine kinases, such as VEGFRs, MET, RET, and the TAM family (TYRO3, MER, AXL). In August 2024, the FDA accepted a supplemental New Drug Application (sNDA) for cabozantinib to treat patients with advanced pancreatic neuroendocrine tumors (pNET) and extra-pancreatic neuroendocrine tumors (epNET) who have previously undergone treatment. The FDA set a PDUFA target date of April 3, 2025, for review and granted orphan drug designation for pNET. This application is supported by data from the Phase III CABINET trial, which studied CABOMETYX in these patient populations. ITM-11 (177Lu-edotreotide) , developed by ITM Isotope Technologies Munich , is a novel Targeted Radionuclide Therapy that combines two components: Edotreotide (DOTATOC), an octreotide-based somatostatin analog, and EndolucinBeta (n.c.a. lutetium-177 chloride), a low-energy beta-emitting synthetic radioisotope. It is currently under investigation in two Phase III clinical trials: COMPETE (NCT03049189) and COMPOSE (NCT04919226). COMPETE focuses on assessing ITM-11 for treating Grade 1 and Grade 2 GEP-NETs, while COMPOSE investigates its use in patients with well-differentiated high Grade 2 and Grade 3 GEP-NETs. ITM-11 was granted orphan designation for GEP-NET treatment based on Phase II data showing significant improvement in PFS. The other pipeline therapies for neuroendocrine tumors include RYZ101 (ACTINIUM-225 DOTATATE): BRISTOL MYERS SQUIBB/RAYZEBIO CAM2029: Camurus ALPHAMEDIX (212PB-DOTAMTATE): RADIOMEDIX/ORANO MED [212PB] VMT-α-NET: PERSPECTIVE THERAPEUTICS ELC-100 (ADVINCE): ELICERA THERAPEUTICS ONC201: CHIMERIX EO2401 + NIVOLUMAB: ENTEROME TIRAPAZAMINE (TEC-001): TECLISON It is more important than ever to ensure and understand supply chain and manufacturing issues of radiopharmaceuticals to stay at the forefront of radiopharmaceutical innovation, especially since a number of companies are investigating radiopharmaceuticals. Emerging key players should make sure that their product, supply, and production capabilities are adequate, and they should be prepared to meet the challenge of offering new therapeutic approaches to cancer patients who otherwise have limited options. In June 2024, BMS-RayzeBio was forced to pause a phase III trial due to an actinium shortage. Oncolytic virotherapy holds promise for cancer treatment. Oncolytic virotherapies like ELC100 (Elicera Therapeutics) and SVV-001 (Seneca therapeutics) are also being investigated for the treatment of NETs in early clinical trials. The anticipated launch of these emerging therapies are poised to transform the neuroendocrine tumors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the neuroendocrine tumors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about NETs clinical trials, visit @ Neuroendocrine Tumors Treatment Drugs Neuroendocrine Tumors Market Dynamics The neuroendocrine tumors market dynamics are anticipated to change in the coming years. NETs are often diagnosed at an early stage due to the hormonal symptoms they produce, allowing for timely intervention and better outcomes, and with advancements like LUTATHERA being the first therapy specifically approved for pediatric patients with GEP-NETs, along with continued research in targeted therapies such as somatostatin analogs and molecular inhibitors, there are growing opportunities for more effective and personalized treatments ; participation in clinical trials can further drive the discovery of new treatment modalities and improve patient outcomes. Furthermore, many potential therapies are being investigated for the treatment of NETs, and it is safe to predict that the treatment space will significantly impact the NETs market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the NETs market in the 6MM. However, several factors may impede the growth of the neuroendocrine tumors market. Since most of the NET cases comprise GEP-NETs, the lack of awareness among healthcare professionals and the general public often leads to delayed diagnosis and treatment . GEP-NETs are a heterogeneous group of tumors with diverse clinical presentations, making it difficult to develop standardized treatment protocols. Additionally, challenges in research and development , such as limited funding and resources, hinder advancements in the field, while the complexity of diagnosing GEP-NETs increases the risk of misdiagnosis or delayed diagnosis, resulting in suboptimal treatment outcomes. Moreover, neuroendocrine tumor treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the NETs market growth may be offset by failures and discontinuation of emerging therapies , unaffordable pricing , market access and reimbursement issues , and a shortage of healthcare specialists . Scope of the Neuroendocrine Tumors Market Report Neuroendocrine Tumors Therapeutic Assessment: Neuroendocrine Tumors current marketed and emerging therapies Neuroendocrine Tumors Market Dynamics: Conjoint Analysis of Emerging Neuroendocrine Tumors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL’s views, Analyst’s views, Neuroendocrine Tumors Market Access and Reimbursement Discover more about neuroendocrine tumor drugs in development @ Neuroendocrine Tumors Clinical Trials Table of Contents Related Reports Neuroendocrine Tumors Epidemiology Forecast Neuroendocrine Tumors Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted NETs epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan. Neuroendocrine Tumors Pipeline Neuroendocrine Tumors Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NETs companies, including RayzeBio, Inc., Seneca Therapeutics, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp & Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals, among others. Gastroenteropancreatic Neuroendocrine Tumors Market Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GEP-NET companies including Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limite, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc, Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, among others. Gastroenteropancreatic Neuroendocrine Tumors Pipeline Gastroenteropancreatic Neuroendocrine Tumors Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GEP-NET companies, including Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., Chimerix, among others. Pancreatic Neuroendocrine Tumors Market Pancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PNET companies including Novartis Pharmaceuticals, Pfizer, Keyrus Biopharma, Merck Sharp & Dohme LLC, Pfizer, Apices Soluciones S.L., Pharmacyclics LLC, Ipsen, among others. Oncology Conference Coverage Services DelveInsight’s Oncology Conference Coverage Services offer a thorough analysis of outcomes from major events like ASCO, ESMO, ASH, AACR, ASTRO, SOHO, SITC, the European CAR T-cell Meeting, and IASLC. This detailed examination provides businesses with essential insights for competitive intelligence and market trend forecasting, supporting the formulation of future strategies. Other Business Consulting Services Healthcare Competitive Intelligence Healthcare Licensing Services Healthcare Portfolio Management Case Study Learn how the engagement with respected KOLs bolstered the client's reputation as a leader in the pharma industry at KOL Profiling About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn | Facebook | Twitter

Aston Villa boss Unai Emery has set his sights on automatic qualification to the last 16 of the Champions League after a 3-2 win at RB Leipzig. Ross Barkley’s 85th-minute goal gave them victory in Germany after goals from John McGinn and Jhon Duran early in each half were cancelled out by Lois Openda and Christoph Baumgartner. That sent them up to third in the new league phase of the competition ahead of Wednesday’s games and with matches against Monaco and Celtic to come, Villa have an excellent chance of finishing in the top eight. Job done... in the end 😅 — Aston Villa (@AVFCOfficial) That would mean they would avoid a play-off round to make it through to the last 16 and Emery says that is the target. “Today was key. Juventus at home, we were thinking more to win but in the end we accepted the draw because it was important for a point to be more or less in the top 24,” he told Amazon Prime. “Today was a match we were thinking at the beginning was key to be a contender to be in the top eight with the last two matches to be played. “It is going to be difficult and we have to get some more points but we now have the possibility to achieve this option. “We are going to enjoy and try to get top eight but we have to be happy because we are in the top 24 and maybe even the top 16. “We weren’t contenders in the beginning to get there but now we have to accept it.” Leipzig, who are flying high near the top of the Bundesliga, are out after losing all six matches. They did pose a threat to Villa, who inflicted some of their own problems on themselves, notably a rare gaffe from goalkeeper Emiliano Martinez for Openda’s equaliser. But Emery was happy with his side’s performance. “I try to enjoy and always we want to improve and sometimes it is hard but today the team were performing well, playing seriously and I was enjoying it,” he added. “We tried to overcome the mistakes we made and we did. More or less we were playing consistently. One mistake and they score but then we played very well. “Champions League is very difficult and we have to expect that every team playing at home are feeling strong. We played with consistency and domination.”None

Wednesday, December 25, 2024 Travelers around the globe continue to place significant trust in friends and family when planning trips, with 58% citing recommendations from personal connections as their primary resource for travel decisions. These findings, based on recent consumer behavior research, highlight the enduring importance of word-of-mouth advice in shaping travel trends. Despite the digital age offering numerous alternatives, such as online travel agencies (OTAs) and search engines, personal recommendations remain the most trusted source of information. Personal connections remain the cornerstone of travel planning for a majority of consumers. The authenticity and trustworthiness of friends’ and family’s experiences have made them a preferred resource, especially in a travel landscape filled with overwhelming digital options. Whether choosing a destination, finding accommodation, or deciding on activities, the influence of personal recommendations transcends demographic boundaries. For the latest travel news, updates and deals, subscribe to the daily TTW newsletter . While friends and family lead in influence, general search engines are a close second, with 51% of travelers using platforms like Google and Bing to research trips. Search engines provide convenience and access to a vast amount of information, enabling users to compare destinations, read reviews, and find competitive prices. The integration of artificial intelligence (AI) into search tools has further enhanced the traveler’s ability to gather tailored recommendations and dynamic itineraries. Online travel agencies, accounting for 41% of travel planning influence, remain a critical component of the booking process. OTAs such as Expedia, Booking.com, and Agoda provide a one-stop shop for researching, comparing, and booking travel services. These platforms excel in showcasing user reviews, pricing transparency, and flexible payment options, making them indispensable for many travelers. Despite their role in hotel bookings, OTAs have yet to dominate airline ticket purchases. Research shows that direct airline bookings, which historically held a strong preference among travelers, have now dropped to levels matching OTA usage for flights. This shift reflects growing competition, pricing transparency, and convenience offered by OTAs. Direct airline bookings, once considered the go-to method for purchasing tickets, have seen a decline. The decrease can be attributed to several factors: For the latest travel news, updates and deals, subscribe to the daily TTW newsletter . In the hospitality sector, OTAs continue to dominate as the preferred booking channel for hotels. This trend is driven by the sheer variety of options available on OTA platforms, as well as detailed user reviews and ratings that assist travelers in making informed decisions. Hotels are increasingly leveraging these platforms to reach broader audiences, even as they attempt to encourage direct bookings through exclusive discounts and loyalty programs. As consumer behaviors evolve, several notable trends are shaping the travel planning and booking landscape: The enduring reliance on friends and family for trip planning is expected to persist, even as digital tools continue to evolve. However, as technology becomes more integrated into the travel experience, it is likely that a hybrid approach will dominate, blending personal recommendations with digital convenience. Industry players must adapt to these changing dynamics by focusing on: The interplay between traditional and digital influences will remain a defining characteristic of travel planning in the coming years. By understanding and catering to these preferences, the travel industry can better meet consumer expectations and foster growth in an ever-evolving market. Read Travel Industry News in 104 different regional platforms Get our daily dose of news, by subscribing to our newsletters. Subscribe here . Watch Travel And Tour World Interviews here . Read more Travel News , Daily Travel Alert , and Travel Industry News on Travel And Tour World only.NB-4746 is under clinical development by Nura Bio and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic Lateral Sclerosis have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. NB-4746 overview NB-4746 is under development for the treatment of amyotrophic lateral sclerosis, multiple sclerosis (MS), traumatic brain injury (TBI), and chemotherapy-induced peripheral neuropathy (CIPN). The drug candidates act by targeting sterile alpha and TIR motif containing protein 1 (SARM1) protein. It is administered through oral route. Nura Bio overview Nura Bio is a clinical-stage biopharmaceutical company that develops neuroprotective small molecule therapies for the treatment of neurological diseases. The company’s lead product candidate, NB-4746 targets SARM1, a neuronally enriched nicotinamide adenine dinucleotide hydrolase that functions as a significant axon-intrinsic metabolic sensor and central driver of axon degeneration. It also develops therapies for various neurological diseases such as amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury and chemotherapy-induced peripheral neuropathy. Nura Bio is headquartered in South San Francisco, California, the US. For a complete picture of NB-4746’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .